VC-backed Rhythm Pharmaceuticals goes public
Boston-based Rhythm Pharmaceuticals Inc, a developer of peptide therapeutics that treats rare genetic deficiencies, has debuted its IPO after pricing its over 7 million shares at $17 per share. The stock began trading October 5, 2017 on the NASDAQ under the ticker symbol "RYTM." Morgan Stanley, BofA Merrill Lynch and Cowen are the lead underwriters. Rhythm Pharmaceuticals' pre-IPO backers include New Enterprise Associates, Third Rock Ventures, MPM Capital, OrbiMed and Pfizer.
5 October 2017•2 mins read
